New test predicts chemotherapy resistance, personalizing cancer treatment

A new test accurately predicts chemotherapy resistance, potentially sparing patients from unnecessary side effects. The test identifies whether a tumor will resist treatment by analyzing its DNA structure. Developed by the University of Cambridge, the test was tested on 840 patients with various cancers, including ovarian, prostate, and breast cancers. It aims to classify patients as either chemotherapy-resistant or sensitive. This advancement could revolutionize cancer treatment by personalizing chemotherapy plans and reducing the use of a treatment that has remained largely unchanged for decades.